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ABSTRACT To understand the basis for T-cell-specific
induction of interleukin 2 (IL-2), we have analyzed nuclear
factors from the Jurkat T-lymphoid leukemia cell, which can
be induced to secrete IL-2. We have used an electrophoretic
mobility shift assay to examine binding of proteins to the
upstream regulatory region, before and after activation with
mitogens. We find two types of binding sites. One resembles an
inducible enhancer element, but the protein that recognizes it
is found in non-T cells and is unlikely to determine T-cell-
specific expression of IL-2. A second site negatively regulates
expression in resting T cells. A complex that binds to a DNA
fragment containing this site is modified only when IL-2 is
expressed, and it lies near a specific inducible DNase hyper-
sensitive region. We suggest that negative regulation at this
site, mediated by its associated protein(s), may contribute to
the cell-specific expression of IL-2.
Activation of inducer T cells by mitogens or antigens leads to
the synthesis of several cell-specific gene products; among
the newly activated genes is that for interleukin 2 (IL-2).
This factor is encoded by four exons spanning -6.5 kilo-
bases (1-3). Its expression is restricted to T cells (4), and its
induction is dependent on increased rates of transcription
(5-7). By using an electrophoretic mobility shift assay
(8-12), we have analyzed binding to regulatory regions of
IL-2. Several regulatory regions have been defined (7, 13).
One positive regulatory element lies between positions - 319
and - 264. It is contained in a larger region (positions - 319
to - 127) that may function as an inducible enhancer (7, 13),
similar to other such elements (14-17). A second region,
more proximal to the "TATA box" (positions - 81 to + 51),
may serve as a promoter for a heterologous enhancer (7). A
T-cell-specific inducible DNase I hypersensitive region has
been defined near this promoter element at position -85
(18).
To identify the proteins that regulate IL-2 transcription
and define their mechanism of activation, we have analyzed
binding of proteins from resting and activated Jurkat cell
nuclear extracts to radiolabeled DNA probes derived from
the IL-2 regulatory region. We have defined several binding
regions. The nucleotides required for binding to one site
have been identified by methylation interference analysis.
Mutations that disrupt binding to this site lead to an increase
in IL-2 promoter-dependent gene expression in resting T
cells. Because of its proximity to an inducible T-cell-specific
hypersensitive site, we suggest that this site may be associ-
ated not only with negative regulation of IL-2 transcription
but also with the determination of its T-cell-specific expres-
sion.
MATERIALS AND METHODS
Cell Lines and Extracts. Jurkat and EL4 cells were main-
tained in RPMI 1640 medium containing 5% (vol/vol) heat-
inactivated fetal bovine serum, penicillin at 50 units/ml, and
streptomycin at 50 Ag/ml at cell densities between 0.2 and
1.5 x 106 cells per ml. Jurkat cells were activated by
incubation with 1 nM phorbol myristate acetate (PMA)
(Sigma) and phytohemagglutinin (PHA) at 2 gg/ml (Phar-
macia). These agents were added 24 hr after transfection and
maintained for an additional 20 hr in culture. EL4 cells were
incubated in a similar fashion with 1 nM PMA to activate
IL-2 secretion.
Nuclear extracts were prepared from uninduced or acti-
vated Jurkat cells as described by Dignam et al. (19), and
protein concentration was determined by using the Bradford
assay with bovine serum albumin standards. Extracts were
prepared also from the following cell lines: MEL, mouse
erythroleukemia cells; L cells, mouse fibroblast line; PD31,
mouse Abelson leukemia virus transformant that represents
a pre-B cell line, because it contains a rearranged (variable/
diversity/joining; VDJ) heavy chain locus; BW5147, mouse
AKR strain thymoma; RLd-11, mouse radiation leukemia
induced thymoma; W7, mouse thymoma; 70Z, mouse pre-B
cell leukemia. None of these cell lines secretes detectable
IL-2.
Plasmid DNA and Probes. Genomic IL-2 plasmid, pURg-
HIL2-1(2), kindly provided by W. Fiers (State University of
Ghent, Belgium), was digested with Sau3A and cloned into
the BamHI site of pUC13. A 632-base-pair Rsa I fragment
was then subcloned into the Sma I site ofp1O6CAT (20). The
DNA probe for the A region was prepared from a fragment
digested with Nla III and Alu I (positions - 355 to - 238) and
ligated into the Sph I and Sma I site of pUC18. The DNA
probe for the B region was prepared from an Mnl I fragment
(positions - 144 to + 39) of the IL-2 upstream sequence
subcloned into the Sma I site of pUC13.
SV-IL2-CAT was prepared as follows: The B probe,
subcloned into the pUC13 plasmid was digested with Xba I
and Sac I, isolated, and cloned into Xba I- and Sac I-
digested p1O6CAT plasmid (20) [kindly provided by M.
Gilman (Cold Spring Harbor Laboratory)], treated with calf
intestinal phosphatase. This plasmid was digested with Hin-
dIII, treated with the Klenow fragment of DNA polymerase
I, isolated, treated with calf intestinal phosphatase, and
ligated to an isolated fragment containing the simian virus 40
enhancer removed from a BamHI site that had been incu-
bated with Klenow fragment of DNA polymerase I.
Abbreviations: CAT, chloramphenicol acetyltransferase; IL-2, in-
terleukin 2; PHA, phytohemagglutinin; PMA, phorbol myristate
acetate.
§Present address: Howard Hughes Medical Institute, MSRB I,
Room 4510, University of Michigan Medical Center, Ann Arbor,
MI 48109.
2934
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Proc. Natl. Acad. Sci. USA 85 (1988) 2935
Gel Binding Analysis and Methylation Interference. Nu-
clear extracts were prepared and incubated with radiola-
beled probes as described (8-12, 14). For reactions with
probe A, 1 pug of poly[d(IC)] was used as competitor, and 4
gg was included with probe B and immunoglobulin promoter
(octamer) probes (12).
Methylation interference was performed as described (21)
by using extracts from Jurkat cells activated for 24 hr with
PMA (1 nM) and PHA (2 gg/ml).
Chloramphenicol Acetyltransferase (CAT) Assay. Cell ex-
tracts were prepared for CAT assay 44 hr after DEAE-
dextran transfection and after activating cells for the last 20
hr of culture. CAT activity was determined as described (14)
and expressed as the percent conversion of chloramphenicol
to its acetylated forms.
DNA Transfection. Plasmid DNAs (10 Iug) were transfec-
ted into Jurkat or EL4 cells (107 cells) by using DEAE-
dextran as described (14).
RESULTS AND DISCUSSION
To identify regulatory sites recognized by DNA-binding pro-
teins, radiolabeled DNA probes were prepared from ==600
base pairs of sequence upstream from the IL-2 transcriptional
start site. Nuclear proteins were extracted from Jurkat cells-
either untreated or activated with PHA and PMA-and incu-
bated with these probes. The three regions that showed
alterations in amount or mobility of DNA-protein complexes
after activation were studied further. The first probe (probe
A, Fig. 1) was derived from a region shown to contain a
sequence required for induction of IL-2 transcription by
deletion mapping (7, 13). A DNA-binding protein appeared in
nuclear' extracts after activation with PMA and PHA that
bound to probe A (Fig. 2A). Similar to other inducible
enhancer binding proteins, this activity was barely detectable
in uninduced cells. The specificity of binding was confirmed
by competition studies. Addition of an unlabeled DNA frag-
ment representing the A site specifically inhibited formation
of the complex with probe A (Fig. 2E, lanes 2 and 3), whereas
an immunoglobulin promoter fragment had no effect (Fig. 2E,
lanes 6 and 7). Inclusion of unlabeled B site fragments also
prevented complex formation (Fig. 2E, lanes 4 and 5), sug-
gesting that the related A-site motif in the B probe (Fig. 1)
may also compete with the A probe.
By using a radiolabeled fragment from the second region
(probe B, Fig. 1), we found a qualitative change in the
pattern of binding after activation. Two slowly migrating
complexes in uninduced extracts disappeared as a new faster
migrating band appeared after activation (Fig. 2B). A third
probe (probe B', Fig. 1) showed a pattern of binding similar
to that seen with probe B (Fig. 2Q. In contrast, minimal
difference in binding to an immunoglobulin promoter frag-
ment was observed in these nuclear extracts (Fig. 2D). The
binding specificity of these radiolabeled probes was con-
firmed by competition studies. When unlabeled probe B was
included in the reaction mixture with radiolabeled probe B,
the slowly migrating complexes were not seen (Fig. 2F, lanes
2 and 3), suggesting a specific interaction. Similarly, incuba-
tion with a fragment derived from the B' region prevented
formation of complexes with probe B (Fig. 2F, lanes 4 and
5), suggesting that the fragments contain related binding
sites. A fragment derived from immunoglobulin promoter
did not inhibit complex formation (Fig. 2D, lanes 6 and 7).
We determined the binding sequences at the B site by using
a methylation interference assay (21) and extracts from
induced cells to define bases critical for contact (Fig. 2G).
The sequence of the B site shown in Fig. 1 is based on the
critical contact residues detected and homology with the
upstream B' sequence.
To determine which factors might determine T-cell spec-
ificity, we analyzed binding to A and B sites in non-T cells.
Nuclear extracts were prepared from several cells types and
analyzed by using the electrophoretic mobility shift assay.
Although the level of expression varied, complexes that
comigrated with the A-site-binding factor were found in
several cell types, most notably in PD31, a pre-B cell (Fig.
3A, lane 3), and the non-IL-2-producing early T cell RLd-11
(Fig. 3A, lane 5). While nuclear factors that recognized the B
site were found in non-T cells, all produced the slowest
migrating band seen in uninduced Jurkat cells (Fig. 3B, lanes
1-7). This complex disappeared in Jurkat cells activated to
secrete IL-2 (Fig. 3B, lane 8). To determine whether the
changes in binding to these sites occurred following activa-
tion in a non-T cell, we prepared nuclear extracts from the
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FIG. 1. Definition ofDNA probes and the location and sequence of protein-binding sites in the IL-2 upstream region. Sequence and position
of several IL-2 regulatory sites have been described (7, 13). Probes A and B were prepared as described. Site A' is deduced from deletion
mapping studies (7), and site B was determined as described in Fig. 2G.
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FIG. 2. Induction and specificity of IL-2-binding factors in Jurkat cells. Analysis of binding of nuclear factors to IL-2 regulatory regions
by using electrophoretic mobility shift assay. Nuclear extracts (14, 19, 22) from uninduced (-) or induced (+) Jurkat cells were incubated with
radiolabeled probe A (A), probe B (B), probe B' (C), or immunoglobulin (Ig) promoter probe (D). The specificity of binding to the A site was
determined by competition with known DNA fragments (E). Nuclear extracts from induced Jurkat cells were incubated with radiolabeled probe
A (see Fig. 1) alone (E, lane 1), in the presence of the indicated amounts of unlabeled fragment A (E, lanes 2 and 3), unlabeled fragment B (E,
lanes 4 and 5), or an immunoglobulin promoter fragment (E, lanes 6 and 7). Specificity of binding to the B site (F), was assessed with nuclear
extracts from uninduced Jurkat cells incubated with probe B alone (F, lane 1) or in the presence of the indicated amounts of unlabeled B site
fragment (F, lanes 2 and 3), B' site fragment (F, lanes 4 and 5), or Ig promoter fragments (F, lanes 6 and 7). Analyses of sequences required
for binding to the B sites were performed (G) in induced Jurkat cells labeled on the coding and noncoding strand by the methylation interference
assay (21). Preparative binding reactions were performed with partially methylated B probe by using extracts from activated Jurkat cells. The
bound (lanes B) and free (lanes F) fragment bands were eluted from a low-ionic-strength polyacrylamide gel, treated with piperidine and
analyzed on an 8% sequencing gel. Jurkat cells were activated with PMA and PHA for 2 hr or 24 hr before preparation of nuclear extracts (14,
19, 22). Extracts from activated cells prepared at 2 hr were used to detect complexes bound to radiolabeled probe A, and those made at 24 hr
were used with radiolabeled probes B and Ig promoter.
pre-B cell line 70Z that expresses immunoglobulin light chain
but not IL-2 after stimulation with PMA or lipopolysaccha-
ride. Stimulation of 70Z cells leads to the appearance of
another DNA-binding protein, NF-KB, that is central to the
activation of immunoglobulin light chain transcription
(15, 21). As with NF-KB, activation of 70Z cells led to -the
appearance of factor binding to the A site in <2 hr after
treatment (Fig. 3C). Similar to NF-KB, appearance of bind-
ing activity is insensitive to cycloheximide (data not shown)
and binding disappears by 20 hr. In contrast, no change was
observed in binding to the B probe in the same extracts from
activated 70Z cells (Fig. 3D), even after 24 hr. This result,
the cellular distribution of the B site (Fig. 3B), and the
definition of a specific inducible hypersensitive site in this
region (18) suggest that it may play a role in the T-cell-
specific induction of IL-2.
To evaluate function of the IL-2 B site, we prepared a
plasmid, SV-IL2-CAT, containing the CAT gene linked to
E
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FIG. 3. Analysis of binding to A and B sites. Nuclear extracts
from the indicated cell lines were incubated with radiolabeled probe
from the A region (A) or B region (B) in the electrophoretic mobility
shift assay. To assess induction following activation of a non-T cell,
nuclear extracts from line 70Z were prepared after treatment with
lipopolysaccharide (LPS at 10 jug/ml) or PMA (1 nM) for the
indicated times and incubated with a radiolabeled DNA probe from
the A region (C) or B region (D). The arrows indicate the position of
the relevant complex.
the first 145 base pairs of the IL-2 upstream region and
simian virus 40 enhancer (Fig. 4A). This enhancer was
included so that significant CAT activity could be detected in
uninduced Jurkat cells. Another plasmid, SV-IL2-CATAB,
made by site-directed mutagenesis, was altered only at bases
critical for binding to the B site (Fig. 4A). These plasmids
were transfected independently into Jurkat or mouse EL4
T-lymphoma cells. In both T cells, after activation by PMA
and PHA, the mutant and wild-type plasmids were equally
active (Fig. 4B), implying that the B site does not control
induced activity levels. By contrast, the wild-type construct
showed a much lower activity in nonactivated cells than did
the mutant con$ruct (Fig. 4B). This result implies that the B
site is important for repression of IL-2 gene transcription in
nonactivated T cells.
We have described several nuclear factors that recognize
binding sites upstream of the IL-2 gene. It is likely that these
DNA-binding proteins are factors that regulate transcription
of the gene. The sequences they recognize contain regula-
tory regions, defined by deletion mapping (7, 13). In addi-
tion, chromatin changes have been detected near these sites
in vivo. Two upstream DNase hypersensitive sites have been
described in Jurkat cells (18): one is constitutive and local-
ized near the A site at position - 306, and the second is
inducible at position - 86 (near the B site). Whereas several
FIG. 4. Function of the IL-2 B site. (A) To assess the function
of the B site, plasmid SV-IL2-CAT was constructed. Mutant SV-
IL2-CATA&B, derived by site-directed mutagenesis (14), was identi-
cal except for the indicated base changes at the B site that inactivate
binding. SV-40, simian virus 40. (B) SV-IL2-CAT (10 ,Ag) or SV-
IL2-CATA&B (10 tag) were transfected into the indicated cell lines by
using DEAE-dextran (23) and incubated at 370C for 44 hr. Activated
Jurkat cells were treated with PHA-P (.2 /Ag/ml) and PMA (1 nM) for
the final 20 hr before preparation of extract for CAT assay. Induced
EL4 cells were treated with PMA (1 nM) for the final 20 hr before
assay. CAT expression was normalized to the level of expression in
activated cells and represents the average of at least three indepen-
dent transfections. The level of expression in activated cells by
using SV-IL2-CAT and mutant plasmid did not differ significantly
(<10o%) when transfections were performed simultaneously with the
same DEAE-dextran solution and ranged from 5 to 30o CAT
conversion. -, Unstimulated; +, stimulated.
sites are necessary for expression of the IL-2 gene (7, 13),
our data show that changes in binding to the B probe
correlate with IL-2 production in T cells. One protein that
binds to this probe recognizes a potential negative regulatory
site near the T-cell-specific inducible DNase hypersensitive
site (18), suggesting that this factor may play a crucial
negative role in determining tissue-specific expression of
IL-2.
The presence of the B-site-binding protein is associated
with decreased IL-2 promoter-dependent expression in non-
activated T cells. Several elements are present near the B
region. Fujita et al. (7) have shown that sequences down-
stream of position -81, containing only part of the B site
described here (see Fig. 1), may serve as a promoter for a
heterologous enhancer. They have also described an element
between positions - 145 and - 127 (the A' site, Fig. 1)
required for upstream sequence to function as an inducible
enhancer. This sequence is highly homologous to a consen-
sus binding site described by sequence comparison in the
upstream regulatory region (7), suggesting that the A' site
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may positively regulate IL-2 transcription and is necessary
but not sufficient for activation.
It has become apparent that the enhancers of several
inducible genes, including P interferon (24, 25), c-myc (26),
c-fos (27), and possibly the sea urchin histone 2B gene (28)
may be composed of distinct subregions that contain positive
and negative regulatory elements. The activation of IL-2
synthesis requires the presence of positive regulatory en-
hancer-like sequences in the upstream region (7, 13). We
have found an inducible DNA-binding factor that binds to
this region, but its presence and induction are not restricted
to T cells. Changes in binding to the B region, however, are
correlated with T-cell-specific activation (Fig. 3, and see also
ref. 18), raising the possibility that this site, associated with
negative regulation, may play a role in determining T-cell-
specific expression of IL-2.
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